It is thus at least possible that the association of ABCG2 polymorphisms with clinical outcomes of NSCLC patients receiving platinum-based chemotherapy could be due to sampling and ascertainment biases and population stratification. This evidence concerns the gene ABCG2 and non-small cell lung carcinoma.